Table 2.
Secondary endpoints in the AZA-001 trial comparing azacitidine (AZA) to conventional care regimens (CCR)
| AZA | CCR | Pvalue | |
|---|---|---|---|
| Remission rate (CR + PR, %) | 29 | 12 | 0.0001 |
| Time to AML transformation (months) | 26.1 | 12.4 | 0.004 |
| Transfusion independence (%) | 45 | 11 | <0.0001 |
| Rate of infections requiring antibiotics | Reduced by 33% in AZA arm vs CCR arm | ||
Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase II study, 223–232,48 Copyright © 2009, with permission from Elsevier.
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; PR, partial remission.